Outcomes of palliative porto-mesenteric venous stenting in unresectable pancreatic malignancies
Palliative transhepatic PV/SMV stenting is a technically feasible and safe procedure in well-selected patients. Symptoms improvement can be seen in most patients. High-volume centers should consider this technique for patients with unresectable tumors who present with symptomatic stenosis or short segment occlusion.
Authors
- Alessandro Fogliati (ORCID: https://orcid.org/0000-0003-0615-3107)
- Mark Joseph Truty (ORCID: https://orcid.org/0000-0003-3776-527X)
- Cornelius A. Thiels (ORCID: https://orcid.org/0000-0003-3654-8601)
- Guido Fiorentini (ORCID: https://orcid.org/0000-0002-1186-1979)
- Scott M. Thompson (ORCID: https://orcid.org/0000-0001-7853-3278)
- James C. Andrews (ORCID: https://orcid.org/0000-0003-1481-2096)
- Andrea Zironda (ORCID: https://orcid.org/0000-0002-0874-1861)
- Thor R Halfdanarson
- Susanne G Warner
- S.K. Adjei Antwi
- Patrick P Starlinger
- Michael L. Kendrick (ORCID: https://orcid.org/0009-0005-7960-3254)
- Chad J. Fleming (ORCID: https://orcid.org/0000-0003-0319-7331)
Institutions
- Mayo Clinic (US)
- WinnMed (US)
- Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
- University of Milano-Bicocca (IT)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1093/oncolo/oyaf267
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00